NSD2 promotes ventricular remodelling mediated by the regulation of H3K36me2

Histone lysine methylation plays an important role in the regulation of ventricular remodelling. NSD2 is involved in many types of tumours through enhancing H3K36me2 expression. However, the role of NSD2 in the regulation of histone lysine methylation during ventricular remodelling remains unclear. In this study, we established cardiac hypertrophy model in C57BL/6 mice by transverse aortic constriction and found that histone lysine methylation participated in ventricular remodelling regulation via the up‐regulation of H3K27me2 and H3K36me2 expression. In addition, we constructed transgenic C57BL/6 mice with conditional knockout of NSD2 (NSD2−/−) in the myocardium. NSD2−/− C57BL/6 mice had milder ventricular remodelling and significantly improved cardiac function compared with wild‐type mice, and the expression of H3K36me2 but not H3K27me2 was down‐regulated. In conclusion, NSD2 promotes ventricular remodelling mediated by the regulation of H3K36me2.

[1]  O. Gavrilova,et al.  Depletion of Nsd2-mediated histone H3K36 methylation impairs adipose tissue development and function , 2018, Nature Communications.

[2]  G. Condorelli,et al.  Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy , 2017, Circulation.

[3]  J. Licht,et al.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[4]  K. Stankunas,et al.  Histone demethylases Kdm6ba and Kdm6bb redundantly promote cardiomyocyte proliferation during zebrafish heart ventricle maturation. , 2017, Developmental biology.

[5]  W. Reik,et al.  The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy , 2017, The Journal of clinical investigation.

[6]  Erin L. Reineke,et al.  Timing and Targeting of Treatment in Left Ventricular Hypertrophy. , 2017, Methodist DeBakey cardiovascular journal.

[7]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[8]  K. Peciak,et al.  Backbone resonance assignments for the SET domain of the human methyltransferase NSD2 , 2016, Biomolecular NMR assignments.

[9]  A. Shilatifard,et al.  Epigenetic balance of gene expression by Polycomb and COMPASS families , 2016, Science.

[10]  V. Schramm,et al.  Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2. , 2016, Journal of the American Chemical Society.

[11]  C. I. Spencer,et al.  KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation , 2016, Development.

[12]  Joshua E. Elias,et al.  A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin* , 2016, The Journal of Biological Chemistry.

[13]  V. Schramm,et al.  Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36 , 2016, Proceedings of the National Academy of Sciences.

[14]  G. Condorelli,et al.  Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure , 2015, Nature Reviews Cardiology.

[15]  T. Huh,et al.  Proper Activity of Histone H3 Lysine 4 (H3K4) Methyltransferase Is Required for Morphogenesis during Zebrafish Cardiogenesis , 2015, Molecules and cells.

[16]  Qing-Jun Zhang,et al.  Histone methylations in heart development, congenital and adult heart diseases. , 2015, Epigenomics.

[17]  X. Dai,et al.  A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. , 2015, Journal of molecular and cellular cardiology.

[18]  T. Gillette,et al.  Readers, writers, and erasers: chromatin as the whiteboard of heart disease. , 2015, Circulation research.

[19]  E. Braunwald.  The war against heart failure: the Lancet lecture , 2015, The Lancet.

[20]  A. El-Osta,et al.  Chromatin modifications remodel cardiac gene expression. , 2014, Cardiovascular research.

[21]  R. Schwartz,et al.  Histone H3 lysine 9 methyltransferases, G9a and GLP are essential for cardiac morphogenesis , 2013, Mechanisms of Development.

[22]  B. Thienpont,et al.  Epigenetics in the heart: the role of histone modifications in cardiac remodelling. , 2013, Biochemical Society transactions.

[23]  Pernette J. Verschure,et al.  Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes , 2012, Nucleic acids research.

[24]  Ching-Pin Chang,et al.  Epigenetics and cardiovascular development. , 2012, Annual review of physiology.

[25]  B. Garcia,et al.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. , 2011, Molecular cell.

[26]  B. Ponder,et al.  Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. , 2011, Neoplasia.

[27]  De-Pei Liu,et al.  The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. , 2011, The Journal of clinical investigation.

[28]  J. Molkentin,et al.  Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. , 2010, Circulation.

[29]  Y. Kaneda,et al.  A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–Hirschhorn syndrome , 2009, Nature.

[30]  Albert Hofman,et al.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. , 2004, European heart journal.